South Australia moves forward with ham sandwich ban and people aren't happy
Don't miss out on the headlines from Lifestyle. Followed categories will be added to My News.
Who's to say what you can or can't put in your kid's lunch box? A lot of people, actually. Just look at the recent stories published about unwanted notes left by teachers and day care workers.
Unhealthy items are often the reason for the left messages, but what's unhealthy exactly? Lollies? Fairy bread? Sure. But what about the good old ham sandwich?
Apparently that's on the list too, and it has caused such a stir in recent times that South Australia has now moved to ban all advertisements that mention the trusty cold meat staple.
Want to join the family? Sign up to our Kidspot newsletter for more stories like this.
Is ham really that bad in a sandwich? Image: iStock
South Australia's ban on ham sandwiches
Recent reports have confirmed that advertisements on ham and salad sandwiches will be banned on South Australia's public transport in a bid to push healthier eating in children and tackle the ongoing issue of adult and childhood obesity in their state.
The ban, which is said to be enforced from July 1st 2025, will not only include cold meats like ham being plastered on the state's buses, trains and trams but will also see any images or mentions of chocolate, lollies, ice cream, soft drinks and other confectionery removed from public viewing.
According to the Australian Association of National Advertisers, it's a "blanket ban" that is uncalled for and a little extreme.
'As it stands, this policy bans all processed meats, which means a simple ham salad sandwich can't be advertised.' AANA CEO Josh Faulks said, according to news.com.au.
'This simply doesn't make sense and the government should be making evidence-based decisions, not blanket bans that don't align with nutritional science.'
RELATED: Parents rage after school bans meat in lunch boxes
Is this really necessary?
When looking at South Australian statistics alone, recent figures have highlighted that 63 per cent of adults and 35 per cent of children across the state are overweight or obese.
If the ban comes into effect, the AANA wants the government to adopt what it calls a 'science-based approach' by using nutrient profiling scoring criteria to determine which foods should be restricted.
For Australian paediatric nutritionist, Susie Burrell, the move is certainly one people in the industry saw coming given recent news about experts wanting parents to stop putting the humble hambo in their kids' lunch boxes.
"The World Health Organisation classifies processed meats including salami, sausages, bacon and devon as Grade 1 carcinogen's, which means that increased consumption is associated with an increased risk of developing cancer, bowel cancer in particular. There are chemicals in both red and processed meat which can damage the lining of the gut which can lead to bowel cancer," Susie tells Kidspot.
"Like many areas of nutrition though, the reality is a little bit more complicated. Not everyone who consumes processed meats will develop bowel cancer. Rather, whether or not individuals develop cancer will depend on a range of other variables including genetics, usual dietary intake, alcohol consumption, among other factors that increase or reduce the risk of cancers developing."
For Susie, a ham sandwich is totally fine to put in your child's lunch box and shouldn't be the main concern for childhood obesity, leading to bans such as the one in South Australia.
"In the diet of an individual who consumes large portions of red and processed meat, as part of a high fat diet with minimal fresh food, the risk overall is greater. While for someone who consumes a ham sandwich on wholegrain bread each day, along with 7-10 serves of fresh fruit and vegetables and minimal processed foods, the risk is significantly lower," she explains.
"This is the issue with targeting a single food within a mixed and varied diet which may offer many other protective factors against cancer development. There is also a big difference in the range of processed meats you can find - some are low in fat; some are nitrate free and some have much more protein and less sodium – they are not all and one the same thing."
The ban covers advertisements on Adelaide's transportation network. Image: NewsWire / Kelly Barnes
How other states should move forward
Back in 2022, the Cancer Council issued a grim warning to parents to stop putting cold, processed meats in their children's sandwiches at school because of the link to increased risk of bowel and stomach cancer.
'We know that ham is a lunch box staple for many families, however, Cancer Council recommends that we limit or avoid processed meats because of their link to increasing the risk of bowel and stomach cancer,' a release from the Cancer Council said at the time.
The Australian Dietary Guidelines said these foods are deemed discretionary, like cakes and biscuits, and should therefore only be eaten occasionally.
For Susie, she'd like to see more manufacturers thinking of better options to put on the market rather than pile on stress for parents about what their children can or can't eat.
"Let's use public health messaging to target the manufacturers of processed meats to make better products that are lower in salt, preservative free and to create innovative products that are better for everyone's health," she says.
"That is where the energy of public health organisations is much better spent and leave the consumer messaging to the clinicians who are much more familiar with the daily stressors the average family is dealing with, especially in relation to packing an appealing and nutritious school lunchbox."
Originally published as South Australia moves forward with ham sandwich ban and people aren't happy
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
3 hours ago
- ABC News
National review launched into IVF accreditation following second Monash embryo mix-up
All Australian states and territories will undertake a review into the implementation of an independent verification body for fertility providers. Victorian Health Minister Mary-Anne Thomas said health ministers met on Friday and agreed to a three-month rapid-review into the sector, which is currently accredited by the Reproductive Technology Accreditation Committee. "It simply doesn't pass the pub test that the people that provide the service are also the ones that determine who provides the service," she said. The announcement comes after two separate embryo mix-ups by Melbourne-based provider Monash IVF were revealed in a matter of months. Ms Thomas said her preference was for the immediate implementation of a regulator, however this was rejected by Queensland Health Minister Tim Nicholls. Ministerial meetings by health ministers operate on a consensus, meaning all ministers must agree to make any changes nationally. "I think it's concerning that there may well be further errors that we don't know about," she said. "And that is because the body that currently accredits fertility care providers is made up of fertility care providers. that's why I find Queensland's position so perplexing." This week, Monash IVF announced to the ASX it would conduct an internal investigation into an embryo mix-up at its Clayton laboratory in Melbourne's south-east earlier this month. That announcement, which came months after the revelation another patient of Monash IVF in Brisbane gave birth to a stranger's baby in 2023, sparked calls for greater regulation of the field. Monash IVF chief executive officer Michael Knaap also resigned earlier this week. On Friday afternoon Mr Butler said he was "really worried about public confidence" in the sector, which he said needed greater transparency and independent accreditation for fertility service providers. "We know that in the last full year there were dozens of breaches of the code of conduct but I don't know, as the federal health minister, what they were," he said. "They are not reported, they are not disclosed." He said health officials across the country would provide advice on whether Australia should move towards national regulations. "There are essentially eight systems of regulation across the country," he said. "It would take a bit of time to move to more national regulation."
ABC News
4 hours ago
- ABC News
Can romantic relationships survive without sex?
How often a couple has sex will fluctuate in most relationships, but what happens when it stops altogether? How one defines a 'sexless marriage' or relationship will vary. But whether it's no sex or infrequent sex over an extended period, couples lacking intimacy is "more common than many think", says Armin Ariana, a sexologist and president of the Society of Australian Sexologists Queensland branch. "This is especially notable in long-term relationships, where sexual activity often declines over time," Dr Ariana says. One Australian study found almost 15 per cent of couples hadn't engaged in sex in the past four weeks. While it's possible people in a relationship might both be comfortable with sex being off the table, a mismatch in desire is more likely at the root of why intimacy is missing, says sexologist and relationship counsellor Tanya Koens, based in the Northern Rivers/Bundjalung Nation. While talking about sex is the first step to reintroducing it, it isn't always easy. "I see people that have been together 30, 40 years, and seen each other throwing up and going through all sorts of terrible situations, and yet they will not talk about sex," says Ms Koens. Sexless relationships can arise for many reasons, both by choice and circumstance, says Brisbane/Meanjin-based Dr Ariana. Desire discrepancy is one of the most common issues he sees for decline in intimacy. "If both partners are on the same page and genuinely OK without [sex], that's not a crisis. "But when one wants connection and the other's switched off, that gap creates real tension." He says it can lead to feelings of frustration, distance and rejection. Other reasons sex may drop off include: No sex or low frequency sex can also be due to body changes including physical pain and disability, adds Ms Koens. Psychotherapist and relationship coach Tracey Rovere from Wollongong/Woolyungah says the less sex a person has, the less they tend to want it. But sex has benefits, she says. "People have sex because it makes them feel good, so they are missing out on getting the oxytocin and the different hormones released during sex." In some cases, couples may choose "to step away from sex", says Dr Ariana, for a variety of reasons. "And they can still have really strong, connected relationships. It's not always about dysfunction; sometimes it's a conscious, mutual decision that works for them." But research shows sexless couples are rarely mutually satisfied with the arrangement. A 2025 study published in the Journal of Family Psychology involving more than 2,100 heterosexual couples found that only 2.3 per cent were both sexless and mutually satisfied. "That doesn't mean it's wrong or impossible — it just means it takes strong alignment and communication to make it work," Dr Ariana says. In seeing couples who aren't having sex, Ms Koens says she approaches it with curiosity. "Why we are saying no to sex? Is it because it's too hard to talk about, or prioritise?" She says "avoidance is a number one strategy" for people not wanting to address issues there might be around sex in the relationship. For those wanting to reignite the spark and have more sex, Ms Koens says to start by focusing on what is possible. She says sex shouldn't be defined as intercourse, because there are many other ways to "have sex" and be intimate without penetration. "Your skin is an erogenous zone, you can be making out on the sofa, dry humping, just doing a bit of heavy petting and then stop. Couples should talk about "what is on the agenda" for that day. Is it just kissing? Or is it giving one person a massage? Is it penetration? "Often people assume, if my husband kisses me then I have to do all the sexual things and I don't feel like it — no," Ms Koens says. "Even just a kiss keeps physical connection." Ms Rovere says for some couples, sex may help establish more of an emotional connection, but others may need the latter first. "Connecting through sex can be a great way to reinvigorate the relationship, whereas other people think 'get the emotional connection back on track, then work towards intimacy and sexual connection'." Dr Ariana says if you're in a sexless relationship and feeling alone, "it's not a failure". "It's a signal to talk, reconnect, or reach out for support. "There's no one-size-fits-all here. What matters is whether it works for you."
News.com.au
4 hours ago
- News.com.au
Scott Power: ASX stocks fall as investors hear mixed news from Cochlear
ASX heath sector falls 1.1% over past five days, while broader markets flat as Middle East tensions flare Cochlear downgrades full-year profit expectations but launches a world first Monash IVF head Michael Knaap resigns after another embryo mix-up Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. It was a big week of news for the ASX healthcare sector with the bourse's fourth largest biotech Cochlear (ASX:COH) downgrading its FY25 net earnings ~4% to $390-400 million, compared with prior guidance in February of $410-430m, on "slower-than-expected sales growth over the last few months". Morgans' healthcare analyst Derek Jellinek wrote in a note to clients consensus for the hearing tech company sat at $411m with Morgans at $412m. While Cochlear continues to expect implant units to grow ~10% in FY25, growth will be weighted to emerging markets as developed market growth has been impacted by slower-than expected market growth and a "small loss" of market share in a few countries. Cochlear now expects services revenue to decline by low double-digits compared to prior expectations for a single-digit decline. "COH believes ongoing work to identify and connect with recipients who could benefit from the latest sound processing technology, combined with the introduction of the new off-the-ear Nucleus Kanso 3 sound processor, which is expected to launch in EU and APAC mid-Jun-25, should lift services revenue in FY26," Jellinek wrote. Following a disappointing H1 FY25 result, Morgans highlighted risks in the services segment (around 25% of sales), driven by slower-than-expected uptake of the Nucleus 8 sound processor, which was launched in FY23, and cost-of-living pressures delaying device replacements. But in some positive news, Cochlear also announced the launch of Nucleus Nexa, the world's first and only smart cochlear implant system, saying it was the "outcome of a 20 year investment in R&D". "A couple of key features include upgraded firmwear, the smallest sound processor and internal memory so that has actually countered the profit downgrade they've announced," Power said. Morgans has a hold rating on Cochlear with a 12-month target price of $285.55. Monash chief quits following another embryo mixup A new acting CEO has been appointed to steer the troubled Monash IVF Group (ASX:MVF), which fell ~27% on Tuesday after reporting another embryo implant bungle. Monash announced on Thursday CEO and managing director Michael Knaap had resigned with CFO and company secretary Malik Jainudeen appointed acting CEO. In the latest incident a patient's own embryo was mistakenly transferred to them, rather than their partner's embryo as specified in the treatment plan at Monash's Clayton laboratory in Melbourne on June 5. Monash said it was conducting an internal investigation to determine the cause of the incident and notified the relevant assisted reproductive technology (ART) regulators, the Victorian health regulator and its insurers. It comes after Monash revealed in April a woman had given birth to a baby that was not hers after receiving the wrong embryo at a Brisbane clinic. An independent review by Fiona McLeod AO SC regarding that incident is currently ongoing and has been extended, with the findings yet to be disclosed. Monash confirmed that its updated profit guidance, issued on May 20, remains unchanged, projecting an underlying NPAT of $27.5 million. Morgans maintains a speculative buy on Monash with a 12-month target price of $1. Israel strikes on Iran add to market uncertainty At 1.45pm on Friday the S&P/ASX 200 Health Care index was down 1.1% for the past five days, while the benchmark ASX 200 was flat for the same period. Markets took a tumble on Friday after reports of Israel strikes against Iran's nuclear sites with the Middle East bracing for retaliation. Power said the escalating conflict adds further complexity to global equity markets still very much being driven by macroeconomic factors and geopolitical tensions. "Markets are still very much broader macro driven including with US President Donald Trump's trade and regulatory policies," Power said. "Investors will now be closely monitoring the escalating tensions in the Middle East." Power's Powerplay: EBR completes raise, starts US rollout EBR Systems (ASX:EBR) is Power's stock of the week after announcing completion of a share purchase plan (SPP) and that the first US commercial patients have been implanted with its WiSE CRT System, the world's only wireless solution for pacing the left side of the heart. The procedures took place at St David's Medical Centre and the Cleveland Clinic, two of several leading US institutions participating in this pilot release of the WiSE CRT System, which was approved by the FDA in April. EBR said the cases represented two of the main indications for WiSE. "Clearly, the first commercial patients implanted with WiSE is a key milestone, as EBR has officially transitioned from a pure R&D focus to a commercial entity," Jellinek wrote in a note to clients. He said importantly, the implants were done in advance of reimbursement and the limited market release of WiSE, which remained on track for October, showcasing the unmet medical need in the initial US$3.6m total addressable market and belief in use of the device. "As this device is a novel treatment option requiring physician education, we view the LMR, targeting key heart failure centres in the US, as an appropriate strategic way to build familiarity and experience, prior to full market release," he wrote. "We see sales surpassing US$80m into CY29. "While certainly not a 'hockey stick', we believe it is a methodical, stage-gated rollout to build strong physician support and closely monitor clinical outcomes, helping to pique interest from any would-be suitor." The company also announced today it had finished its SPP raising $xxm and adding to a fully underwritten Institutional Placement raising $55.9m completed in May. Proceeds from the capital raise will be used to advance its US commercialisation strategy for WiSE. Morgans has a buy rating and 12-month target price of $2.86. Two positive studies for Avita Wounds management company Avita Medical (ASX:AVH) has announced the first clinical publication of its Cohealyx product, which is a collagen-based dermal matrix, in the Journal of Surgery. The publication includes two positive case reports on patients with complex hand wounds treated with Cohealyx. In both instances, the patients sustained full-thickness burns following syncopal episode (temporary loss of consciousness due to a drop in blood flow to the brain). The study showed significant acceleration of wound bed vascularisation and autograft readiness, achieving readiness within five to 10 days compared to the typical two to four weeks. "Clearly, a small sample size and this publication represents the first clinical validation of AVH's preclinical findings but it's a strong start and likely the first of many case-studies to come," Morgans' healthcare analyst Iain Wilkie wrote in a note to clients Avita also announced a new study of its flagship spray-on skin treatment Recell showed it reduced hospital stays by 36% compared to traditional skin grafts. Presented at the British Burn Association's annual meeting, the US-based study analysed outcomes for more than 6,300 patients treated with Recell between 2019 and 2024. All patients had burns covering less than 30% of their total body surface area. The findings showed Recell patients spent on average 6.2 fewer days in hospital, delivering an estimated $300m in healthcare savings over the five-year period. Wilkie wrote that the share price had continued to remain weak following series of missed guidance expectations and dwindling cash reserves. "The point with Avita is they've expanded their product range to treat more of the wound complex and what the market is concerned about is do they need to raise additional funds," Power said. "They've told the market they can see a pathway through to profitability or breakeven by the fourth quarter of this calendar year so as each quarter rolls on we will get more confident that they're able to achieve that." Morgans has a speculative buy rating on Avita and 12-month target price of $3.76. Imricor gets CE Mark for NorthStar Mapping System Imricor Medical Systems (ASX:IMR) has received CE mark (European) certification for its NorthStar Mapping system under the new, more stringent European Union Medical Device Regulations (MDR). NorthStar has been approved as a Class IIa medical device with the certification received ahead of schedule. Imricor is advancing technology for real-time interventional cardiac magnetic resonance (iCMR) ablations, enabling cardiac ablation procedures to be guided by live MRI imaging instead of traditional x-ray fluoroscopy. NorthStar is a key component of its product offering. The certifications follows on from recent European approvals received for its Advantage-MR EP Recorder/Stimulator (Advantage-MR), and its second generation Vision-MR Ablation Catheter. "Imricor will now phase out first generation products approved under the old EU regulations, replacing them with new MDR approved devices," Power said. "We expect sales momentum to steadily build over coming quarters." Power said next catalysts to watch for include additional sales orders in Europe and Middle East and US FDA approval for NorthStar. Imricor is also undertaking its Vision-MR Ablation of Atrial Flutter (VISABL-AFL) pivotal clinical trial to support FDA approval of its products, which it hopes to achieve in 2025. In Europe, where Imricor has already received regulatory approval for atrial flutter, the company has started a pivotal VISABL-VT clinical trial for its second indication, ventricular tachycardia (VT). Morgans has a speculative buy on Monash and 12-month $2.28 target price. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.
